188 related articles for article (PubMed ID: 12605276)
1. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
[TBL] [Abstract][Full Text] [Related]
2. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Ishijima H; Oya N; Sato N; Inoue T; Endo K
Radiology; 2001 Jun; 219(3):774-7. PubMed ID: 11376267
[TBL] [Abstract][Full Text] [Related]
3. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
[TBL] [Abstract][Full Text] [Related]
5. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
9. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
Yamamoto Y; Kawaguchi Y; Kawase Y; Maeda Y; Nishiyama Y
Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
[TBL] [Abstract][Full Text] [Related]
13. Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions.
Nose H; Otsuka H; Otomi Y; Terazawa K; Takao S; Iwamoto S; Harada M
J Med Invest; 2013; 60(3-4):184-90. PubMed ID: 24190034
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
[TBL] [Abstract][Full Text] [Related]
15. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
16. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
[TBL] [Abstract][Full Text] [Related]
17. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
19. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
[TBL] [Abstract][Full Text] [Related]
20. 18FDG PET scanning of benign and malignant musculoskeletal lesions.
Feldman F; van Heertum R; Manos C
Skeletal Radiol; 2003 Apr; 32(4):201-8. PubMed ID: 12652335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
